Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
"It is estimated that 1 in 10 dogs will experience heart disease in their life and unfortunately, most go undetected," said Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica. "Diagnosing and evaluating cardiac disease in our canine patients can be challenging. The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes. This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients' quality of life earlier in the disease process." Additionally, this assay runs on either plasma or serum allowing more flexibility within a clinic's natural workflow.